Finland · Delayed Price · Currency is EUR Nanoform Finland Oyj Earnings Call Transcripts
Fiscal Year 2026
-
Record Q1 revenue and gross margin achieved, with operating costs down 31% year-over-year. Signed first exclusivity deal for biologics, validating technology and attracting strong industry interest. On track for 2026 cash burn target and 2030 growth goals.
Fiscal Year 2025
-
Record revenue and EBITDA growth in 2025, driven by new IP, commercial deals, and expansion in Asia. Cash burn is targeted below €10M for 2026, with a strong cash position and several milestone opportunities ahead. Subcutaneous biologics delivery and GMP project share are key growth drivers.
-
Secured a commercial GMP manufacturing license, expanded product pipeline, and improved cash burn rate to EUR 3.9 million in Q3 2025. Strong cash position and new partnerships support growth, with targets for 2026 cash burn below EUR 10 million.
-
Q2 2025 saw 23% revenue growth, improved cash flow, and a 98% gross margin, with strong progress in both small molecule and biologics platforms. Key milestones include the first license agreement for nanoenzalutamide, ongoing pivotal studies, and expanded global partnerships.
-
Strong Q1 performance with record project growth, reduced cash burn, and expanded pharma partnerships. Key product kernels advanced, including nanoenzalutamide, with pivotal trial preparations and new patent granted. Cash position remains robust, supporting continued innovation.
Fiscal Year 2024
-
Record project signings and revenue growth of 8% year-over-year highlight strong commercial momentum, with pivotal studies and commercial deals for key product kernels expected soon. Manufacturing and clinical milestones remain on track, and cost discipline is emphasized.
-
Record Q3 project signings and a return to revenue growth highlight strong industry demand and commercial traction, especially for nanoenzalutamide and nanoapalutamide. Gross margin is set to exceed 90% as operational efficiencies take hold, with a robust cash position supporting future growth.
-
Nanoforming technology is driving new pharma partnerships, with strong progress in biologics and product kernel development. Revenue and cash flow are improving, and commercial deals are expected to accelerate in H2 2024, supported by a robust balance sheet.